Status:
TERMINATED
Pertussis Acellular Vaccine Adjuvanted With TQL1055
Lead Sponsor:
Adjuvance Technologies, Inc.
Conditions:
Pertussis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study to evaluate the safety and immunogenicity of the semisynthetic saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.
Detailed Description
The recent increase in the incidence of pertussis has prompted the need for improvements to current acellular pertussis vaccines. Use of novel adjuvants is one approach to such improvement. TQL1055 is...
Eligibility Criteria
Inclusion
- Key
- 18 to 50 years of age
- General good health
- BMI between 17 and 35 kg/m2
- Not of childbearing potential OR using adequate contraception
- Key
Exclusion
- Pregnant or lactating
- Prior medical condition that could adversely affect subject safety
- Clinically significant abnormal laboratory parameter
- Current acute febrile illness
- Contraindication to intramuscular injection
- Contraindication to pertussis vaccination
- Received pertussis vaccine within 3 years
Key Trial Info
Start Date :
April 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04793620
Start Date
April 6 2021
End Date
February 14 2022
Last Update
November 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Q-Pharm
Brisbane, Australia